Funding for this research was provided by:
National Institute on Aging (NIA P-30 AG062429)
Received: 29 December 2019
Accepted: 15 June 2020
First Online: 30 June 2020
Ethics approval and consent to participate
: The research protocol was reviewed and approved by the UCSD Human Research Protection Program (HRPP)/Institutional Review Board (IRB). Written informed consent was obtained from all study participants.
: Not applicable.
: The authors report no competing interests related to this research. DPS serves as a paid consultant for Takeda Pharmaceuticals, Inc.; Aptinyx, Inc.; and Biogen, Inc. SDE serves as a paid consultant on Data Safety Monitoring Boards for Lilly USA, LLC and Suven Life Sciences Ltd. JBB has served on advisory boards for Elan, Bristol-Myers Squibb, Avanir, Novartis, Genentech, and Eli Lilly and holds stock options in CorTechs Labs, Inc. and Human Longevity, Inc. DG serves as editor for <i>Alzheimer’s Research and Therapy</i> and as a paid consultant on Data Safety Monitoring Boards for Pfizer, Inc.; Elan, Inc.; and Balance Pharmaceuticals, Inc.